Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors. Issue 13 (21st July 2022)

• Record Type: Journal Article
• Authors: Alam, Sadia; Sadiqi, Shahida; Sabir, Maimoona; Nisa, Sobia; Ahmad, Sajjad; Abbasi, Sumra Wajid
• Is Part Of: Journal of biomolecular structure & dynamics. Volume 40:Issue 13(2022)
• Page Start: 5748
• Page End: 5758
• Publication Date: 2022-07-21
• Subjects: Bacillus subtilis -- COVID-19 -- 3-chymotrypsin-like main protease -- anti-SARS-CoV-2 -- molecular docking -- molecular dynamic simulation -- binding free energy; Biomolecules -- Periodicals; Molecular structure -- Periodicals; Molecular Biology -- Periodicals; Biomechanics -- Periodicals; 572
• DOI: 10.1080/07391102.2021.1873188
• Languages: English
• ISSNs: 0739-1102

Abstract

Abstract: The COVID-19 being a preconized global pandemic by the World Health Organization needs persuasive immediate research for possible medications. The present study was carried out with a specific aim to computationally evaluate and identify compounds derived from Bacillus species as the plausible inhibitors against 3-chymotrypsin-like main protease (3CLpro) or main protease (M Pro ), which is a key enzyme in the life-cycle of coronavirus. The compounds were isolated from the crude extracts of Bacillus species. Among the isolated compounds, novel inhibitory leads were identified using in silico techniques. Molecular docking revealed that stigmasterol (-8.3 kcal/mol), chondrillasterol (-7.9 kcal/mol) and hexadecnoic acid (-6.9 kcal/mol)) among others bind in the substrate-binding pocket and also interacted with the catalytic dyad of the 3-CLpro. Further evaluation using 50 ns molecular dynamic simulation and MMPB-GBSA indicated that among the top three docking hits, hexadecanoic acid was found to be the most promising anti-COVID-19 lead against the main protease. Hexadecanoic acid might serve as a potent anti-SARS-CoV-2 compound to combat COVID-19, however, in vitro and in vivo validation and optimization is needed. Communicated by Ramaswamy H. Sarma